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a b s t r a c t
The involvement of complement receptor 2 (CR2) in B cell tolerance and autoimmune disease has been
revealed over the past decade or so. Our previous studies have established thatmice prematurely express-
ing human CR2 under the control of a lambda light chain promoter (in particular the hCR2high line) have a
markeddeficit in their immune response to various antigens and fail to develop collagen-induced arthritis.
This phenotype appears to be the result of irreversible changes in B cell signalling pathways and suggested
that hCR2 expressing mice are protected from developing autoimmune disease. To test this hypothesis,
we examined the ability of the hCR2 to block the development of spontaneous autoimmune disease on
the C57BL/6j-Faslpr/Faslpr (B6lpr) background. We found that expression of hCR2 on the B6lpr background
resulted in a significant reduction in levels of anti-nuclear antibodies (ANA) generated as mice aged but
the levels of ANA were still higher than those found in age matched C57BL/6j (B6) mice. B cells from
hCR2high mice were found to display a higher baseline level of apoptosis, whether analysed ex vivo or after
in vitro culture, than their B6 counterparts and this was apparently linked to both surface IgM expression
by the B cells and C3 levels in the mice. Our data also provides evidence that B cell survival in the pres-
ence of hCR2 is heavily modified by the background strain of the mouse. Overall, we have demonstrated
that mice expressing hCR2 on their B cells during bone marrow development display a higher degree of
apoptosis which may lead to a deletion of autoreactive B cells and be protective against the development
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. Introduction
The suggestion that complement receptor type 2 (CR2) expres-
ion levels might be important in autoimmune disease arose from
wo studies that noted a marked down regulation of CR2 expres-
ion levels on B lymphocytes isolated from patients with systemic
upus erythematosus (SLE) (Marquart et al., 1995; Wilson et al.,
986). The reduction in CR2 expression levels on B cells as disease
rogressed in a murine model of SLE (the MRLlpr model) further
upported this assertion (Takahashi et al., 1997). Indeed, data gen-
rated using mice deficient in the Cr2 gene (encoding both mouse
R1 andCR2 through alternative splicing; Cr2−/− (Kurtz et al., 1990;
olina et al., 1990)), appeared to confirm that both these proteins
ere important in the development of auto-antibodies in lupus
usceptible mice (Wu et al., 2002). However, probably the most
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ompelling evidence to link CR2 function to the onset of lupus
rose from a study of lupus susceptibility loci in the NZM2410
ice (Boackle et al., 2001). This study identified a genetic poly-
orphism that results in the addition of a novel glycosylation site
n the CR2 protein. This interferes with binding to its main lig-
nd, C3d, and supported previous work suggesting a necessity for B
ell signalling through CR2 in maintaining B cell tolerance (Carroll,
000; Fischer et al., 1996; Prodeus et al., 1998). A genetic polymor-
hism in the human CR2 promoter region (that directly influenced
R2 expression levels) was recently identified in a cohort of SLE
atients (Wu et al., 2007), again suggesting that CR2 expression
evel and/or functionality was highly important in overall B cell
unction.
CR2 is expressed primarily on mature B cells and follicular den-
ritic cells (FDC) in both human and mouse. hCR2 and mCR2 have
high degree of homology both at the nucleotide and protein level
eing approximately 150kDa in size and consisting of an extracel-
ular domain, made of 15 or 16 tandem short consensus repeats
SCR), a transmembrane domain and a short intracellular domain
Fingeroth, 1990; Molina et al., 1990; Moore et al., 1987; Weis et
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cells were washed in staining buffer 3 times and then incu-I.Y. Pappworth et al. / Molecula
l., 1988). However, one important difference between these two
pecies is that hCR2 and hCR1 are the products of two separate
enes whilst mCR1 and mCR2 are the products of one alternatively
pliced gene (Cr2) (Ahearn and Fearon, 1989). In the normal sit-
ation, expression of CR2 on human and mouse B lymphocytes
s restricted to transitional B cells and mature B cells as well as
arginal zone and B-1 B cells (Takahashi et al., 1997; Tedder et
l., 1984). B cells at earlier stages of development do not express
R2. The role for CR2 in the development and maintenance of the
umoral response to T-dependent (TD) antigens (Ags) was first dis-
overed by several in vivo studies using CR1/2 blocking Abs and a
tudy using CR2-IgG fusion protein (Gustavsson et al., 1995; Hebell
t al., 1991; Heyman et al., 1990; Thyphronitis et al., 1991). This
ole was confirmed and expanded by the independent generation,
y gene targeting, of 3 lines of Cr2−/− mice (Ahearn et al., 1996;
aas et al., 2002;Molina et al., 1996). Cr2−/− mice have been shown
o have a defect in response to T-independent (TI) Ag (Haas et
l., 2002) and to T-dependent (TD) antigens (Ahearn et al., 1996;
olina et al., 1996) as well as many other facets of the humoral
mmune response and clearly demonstrate that CR2 is central to
he breadth of B cell function in the mouse (reviewed (Holers,
005)).
CR2 is known to exert potent B cell signalling through non-
ovalent association with CD19 and CD81 (TAPA-1) (Bradbury et
l., 1992; Fearon and Carter, 1995; Matsumoto et al., 1991; Tedder
t al., 1994). The co-ligation of this signalling complex and the B
ell receptor (BCR) are thought to form the basis of CR2s role in the
umoral immune response and in the maintenance of B cell toler-
nce.However, thedefinitive rolesof eachof themolecules involved
antigen coated with C3d, CR2, CD19, CD81 and the BCR) remain an
reaof intense studyanddebate (reviewed (Rickert, 2005)). Inorder
o investigate the role of CR2 in B cell function, we have previously
enerated several distinct hCR2 tg mice (Marchbank et al., 2002;
archbanket al., 2000). ThehCR2high mice expresshCR2during the
arly stages of B cell development unlike endogenous mCR1/2 or
CR2 tg mice created using a hCR2 genomic fragment, (Marchbank
t al., 2000) under the control of a B cell-specific lambda pro-
oter/enhancer minigene. The hCR2high mice display a 40–60%
eduction in mature B cell numbers and the remaining mature B
ells failed to respond adequately in vivo when challenged with
number of TD and TI antigens (Birrell et al., 2005; Kulik et al.,
007; Marchbank et al., 2002). We have recently found evidence
f alteration in tyrosine phosphorylation patterns in response to
CR and CR2/CD19 cross-linking in the hCR2high mice and demon-
trated that these changes protect hCR2high mice from the onset of
n organ specific autoimmune disease collagen-induced arthritis
CIA) (Kulik et al., 2007).
In order to further investigate the resistance of hCR2 tg mice to
nset of autoimmune disease, we crossed the hCR2high mice onto
he B6lpr background. B6 mice do not readily develop autoimmune
isease under normal circumstances (Izui et al., 1984). However,
6 mice deficient for Fas (CD95) develop a mild lupus-like disease
haracterized by lymphadenopathy, splenomegaly and production
f increased titers of IgG antibodies to a variety of auto-antigens
ncluding DNA, anti-nuclear antigens (ANA), and the Fc portion
f autologous IgG (Cohen and Eisenberg, 1991; Izui et al., 1984).
otably, B6lpr mice do not develop the renal failure or arthri-
is associated with the deficiency in Fas in other strains of mice
Cohen and Eisenberg, 1991; Izui et al., 1984; Theofilopoulos and
ixon, 1985; Theofilopoulos et al., 1985). Herein, we show that
xpression of hCR2 in the B6lpr mice significantly reduces the level
f ANA generated and we establish that hCR2 expression on B
ells in the bone marrow results in increased B cell apoptosis at
he point of BCR expression, suggesting an increase in negative
election.
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. Materials and methods
.1. Cells
Peripheral blood lymphocytes (PBL) from mice were collected
nto 20l of heparin via a tail bleed and washed once in cold
BS. Bone marrow B cells were collected by flushing mouse femurs
ith cold PBS. Isolated spleens were ground into single cell sus-
ensions using frosted glass slides and transferred to 15ml conical
ubes on ice. Large debris settled after a 10min incubation and the
upernatant was transferred to a new tube. Cells were pelleted and
ashedoncewith stainingbuffer (PBS, 1%FBS, 0.02% sodiumazide).
ll samples derived from mice were incubated with 0.5–1ml of
mmonium chloride red blood cell (RBC) lysis buffer at room tem-
erature for 1–2min. The cellswere thenwashedwith1ml staining
uffer 1–2 times, counted and 1–3×106 cells/ml used per analysis.
ells were then stained as described below.
.2. Antibodies
Purified and biotinylated (b) 171 (anti-hCR2) and b7E9 (anti-
CR1/2), purified and bIgG1 (isotype control) were produced
n the laboratory from hybridomas following standard meth-
ds. Purified 2.4G2 (anti-mCD16/mCD32, Fc Block), phycoerythrin
PE) conjugated B-Ly-4 (anti-hCR2), fluorescein (FITC) or allo-
hycocynin (APC) conjugated RA3-6B2 (anti-mCD45R, B220),
iotin-conjugated 145-2C11 (anti-CD3), FITC-Annexin V, Propid-
um Iodide (PI) and Streptavidin (SA) – APC were all obtained
rom Pharmingen (BD, Cowley, Oxford). SA–PE and anti-IgM-Cy5.5
ere obtained from Jackson labs (Stratech Scientific,UK). Cas-
ACE (FITC-VAD-FMK) was obtained from (Promega, Madison, WI,
SA).
.3. Mice
The lambda human CR2 transgenic mice (hCR2high and hCR2int)
nd the genomic hCR2 transgenic mouse (P1-5) used in this study
ere generated and screened by PCR and/or flow cytometry as pre-
iously described (Marchbank et al., 2002; Marchbank et al., 2000).
dditional mice used are F7-10 on the Cr2−/− background (Molina
t al., 1996) (confirmed by PCR or flow cytometry using b7E9), F6-
8 on the C3−/− background (screened by ELISA or Western Blot
s previously described (Twohig et al., 2007)), F4 on the DBA1/j
DBA) background or on a C57Bl/6j (B6) background as indicated.
he hCR2high mice on the C57BL/6j-Faslpr/Faslpr (B6lpr) background
ere generated byback crossing for four generationswhilst screen-
ng for homozygous Faslpr defect and hCR2 expression by PCR as
reviously described (Sekine et al., 2001; Marchbank et al., 2002)
B6lpr. hCR2).
.4. Flow cytometry
After RBC lysis, cells were washed and resuspended in 10g/ml
f 2.4G2 antibody in order to block Fc receptors. After 15min
ncubation on ice, cells were washed in staining buffer. Cells
ere resuspended in 100l staining buffer containing primary Ab
0.1–3g/ml) and 1l anti-B220-FITC or APC, where appropriate.
ells were incubated for 30min on ice in the dark. After incubation,ated with the appropriate streptavidin conjugated fluorochrome
o detect biotin labeled primary Abs. Following incubation, cells
ere washed as above and then resuspended in staining buffer
ontaining 1% formaldehyde. Flow cytometry was carried using a
ecton-Dickinson FACS calibur (Oxford, UK).
1 r Immunology 46 (2009) 1042–1049
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Fig. 1. Significantly less ANA are detectable in B6lpr mice which express hCR2.
Serum was collected from 12 C57Bl/6j (B6), 15 C57Bl/6j-Faslpr/Faslpr (B6lpr) and
12 B6lpr.hCR2high (B6lpr.hCR2) mice at 6 month of age and applied to commercially
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.5. Apoptosis analysis
Cells were collected from spleen or bone marrow as described
bove. B cells were identified using B220-APC and incubated with
aspACE according to manufacturers guidance (Promega, UK). On
ome occasions cells were also stained using B220-APC to identify
cells followed by PI and Annexin V FITC apoptosis kit (provided
y BD Pharmingen, Oxford, UK). Samples were then immediately
nalysed by flow cytometer. Alternatively, cells were washed 3x in
PMI before being resuspended at 3×106 cell/ml in RPMI/10% FBS/
.01%2-mercaptoethanol in 24well plates. Plateswere cultured in
tandard conditions for 16h. Cells were then collected and washed
times prior to staining as outlined above.
.6. ANA, dsDNA and ssDNA ELISA
Blood was collected from age and sex matched 12 B6, 15 B6lpr
r 12 B6lpr. hCR2 mice by tail vein nick and allowed to clot. Sera was
hen applied to a quantitative ANA or qualitative ssDNA and dsDNA
LISA as directed by the manufacturers instructions (Autogen Bio-
lear,Wiltshire, UK).
.7. Statistical analysis
Data was analysed and significance between groups was estab-
ished using PrismGraph 3 software. Student’s T test and the
ann–Whitney test were used were appropriate. p<0.05 was con-
idered significant.
. Results
.1. The levels of ANA are significantly reduced in B6lpr.hCR2high
ice
The reliance of the CIA model on adjuvant driven antibody pro-
uction to produce disease (Yanaba et al., 2007) and the inability of
CR2high mice to generate antibody to othermodel antigens (Birrell
t al., 2005; Kulik et al., 2007; Twohig et al., 2007) led us to question
hether the marked protection from disease seen in our previous
IA study (Kulik et al., 2007) was due to an inability to generate
ntibodies to the bovine collagen. To determine whether a similar
ffectwould be seen in the absence of foreign antigen and adjuvant,
e opted to test whether expression of the hCR2 tg could prevent
nsetof spontaneousautoimmunediseaseon theB6lpr background.
ice were backcrossed for 4 generations and serum collected from
t least 12 B6lpr.hCR2high, B6lpr or B6mice as they reached 6months
f age. The levels ofANA inB6lpr.hCR2high micewere found tobe sig-
ificantly reduced compared to B6lpr mice using a quantitative ANA
LISA (Fig. 1a). However, B6lpr.hCR2high mice still generated signifi-
antly higher levels of ANA than age matched B6 mice (Fig. 1a), and
here was no visible difference between these groups of mice with
espect to the levels ofC3and Igdeposition in thekidneyat this time
data not shown). Analysis of ssDNAanddsDNA (Fig. 1b and c) using
semi-quantitative approach confirmed significantly lower levels
f ssDNA auto-antigen but only a slight decrease in dsDNA across
he mice. This suggested some variation in the extent to which cer-
ain auto-antigens were affected as well as underlining that whilst
xpression of the hCR2 tg is clearly protective in this background, it
id not give the relative degree of protection noted in our previous
IA study on the DBA1/j background..2. B cells from hCR2high mice are more susceptible to apoptosis
Our previous studies in hCR2high mice have revealed a marked
hange in activation marker profile of B cells in the periphery that
o
t
t
B
ovailable quantitative ANA ELISA (a) or qualitative anti-ssDNA ELISA (b) or anti-
sDNA ELISA (c) following manufacturers instructions. Significance was calculated
y Students T test. ***p<0.0001, **p<0.001, *p<0.05.
s reminiscent of a mild anergic phenotype (Birrell et al., 2005).
ne marker that was elevated in hCR2high mice was Fas and pro-
ides a potential explanation for the difference in protection noted
etween the B6lpr study and the CIA study, in that the primary
echanism of protection associated with expression of hCR2 could
e the removal of B cells by a Fas dependent apoptosis pathway.
n order to find evidence for this possibility, we looked at the level
f apoptosis in B cells isolated from hCR2high mice as well as addi-
ional lines with lower hCR2 expression levels on their B cells. Prior
o overnight incubation, the level of hCR2 expression on the splenic
cellswas confirmedbyflowcytometry (Fig. 2a) and then the levels
f apoptosis displayed by the B cell populations from B6, hCR2high,
I.Y. Pappworth et al. / Molecular Immunology 46 (2009) 1042–1049 1045
Fig. 2. Apoptosis is increased in HCR2 tg mice. Splenocytes were isolated from littermates of each genotype as indicated in the methods section. (a) Cells were stained with
B220 and b171 to confirm the expression level of hCR2 on B cells isolated from the mice indicated. (b) Cells were incubated overnight in standard tissue culture conditions
and then stained with anti-B220 and FITC-VAD-FMK to identify apoptotic B cells. 3 C57Bl/6j (B6), 5 P1-5 (hCR2 tg), 3 hCR2int and 3 hCR2high mice were examined (each data
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soint is the mean apoptosis value from 3 separate culture wells). (c) Freshly isolated
nd FITC-VAD-FMK (to identify apoptotic cells). Groups of 6 mice were analysed; C
ann–Whitney test was used to establish significance. *p<0.05, **p<0.01.
CR2int and P1-5 mice (genomic hCR2 transgenic mouse express-
ng hCR2 at the correct developmental point and without the B
ell defect (Marchbank et al., 2000)) were established after 16h.
he level of detectable apoptotic B cells in cultures from hCR2high
ice was found to be significantly greater than that of both B6 and
he P1-5 strain of mice and was notably higher than hCR2int mice
Fig. 2b). This finding led us to examine the baseline levels of apop-
osis in freshly isolated BM and splenic B cells from hCR2high mice.
gain, hCR2high mice displayed significantly higher levels of apop-
osis than the B6 littermates (Fig. 2c and d). Examination of C3−/−.
CR2high mice (i.e. devoid of the main ligands for CR2) suggested
hat C3 levelswere particularly important in determining apoptosis
evels during the BM stage of B cell development (Fig. 2c). Analysis
f the splenicB cell population in theC3−/−. hCR2high micealso indi-
ated a reduced level of apoptosis but it was not nearly as marked
Fig. 2d). We found that apoptosis levels after 2h culture were not
ignificantly different from those measured prior to incubation but
uggested that there was an increased rate of apoptosis during cul-
ure (data not shown). Overall, this data infers that expression level
nd/or stage of expression of hCR2 is critical in establishing the sus-
eptibility of B cells to apoptosis in culture and might give a reason
or the differences between the previous CIA study and the current
6lpr analysis.
t
f
(
b
omarrow and (d) Splenocytes were stained with anti-B220-APC (to identify B cells)
(B6), hCR2high (hCR2); C57Bl/6.C3−/−(C3−/−), C57Bl/6.C3−/− .hCR2high (C3−/−hCR2).
.3. C3 restricts hCR2 expression levels on the B cell surface after
IgM expression
We have previously shown that hCR2 expression levels drop
ignificantly as the B cells mature from B220lo to B220hi and are
educed further still as B cells migrate into the periphery (Birrell
t al., 2005). On analysis of B cells isolated from C3−/− hCR2high
ice,we found that this reduction in hCR2 expression levelswas no
onger apparent, essentially leading to an apparent 3-fold increase
n hCR2 expression levels on mature B cells in conjunction with
n improvement in the number of B cells reaching the periphery
Twohig et al., 2007). These previous data, together with the data
howing that apoptosis levels in the BM of C3−/−hCR2high were
educed compared with hCR2high mice (Fig. 2c), led us to look more
losely at the factors involved in the down regulation or selection
f cells with low levels of hCR2 in the presence of C3. Examina-
ion of BM B cells for intracellular and extracellular expression of
IgM, in conjunction with hCR2 surface expression, demonstrated
hat sIgM expressing cells had lower levels of hCR2 on the cell sur-
ace than B cells which had constructed but not expressed sIgM
Fig. 3). These results were confirmed using several different anti-
odies to hCR2 in order to control for the potential loss or blocking
f antibody binding sites due to the presence and binding of newly
1046 I.Y. Pappworth et al. / Molecular Immunology 46 (2009) 1042–1049
Fig. 3. B cells from hCR2high mice express less hCR2 after sIgM expression in the
presence of C3. BM cells were collected from C3+/+hCR2high and C3−/−hCR2high mice
as described in materials and methods. BM lymphocytes were stained for B220+
and hCR2 followed by staining for IgM before (Extracellular) or after (Intracellular)
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Fig. 4. hCR2 expression level is dependent on mouse strain. (a) Representative plots
of BM cells isolated from age and sex matched hCR2high and hCR2int mice on the
DBA/1j and C57Bl/6 background are shown. B220-FITC was used to identify B cells
and hCR2 expression was assessed using biotin-171+SA-PE. R1 and R2 delineate
the B220low (pre/immature) and B220high (mature) B cell population, respectively.
(b) Splenocytes from 8 C57Bl/6.hCR2high (B6hCR2), 9 B6lpr.hCR2high (B6lpr.hCR2), 7
C57Bl/6.C3−/− .hCR2high (C3−/−hCR2) and 5 DBA/1j.hCR2high (DBAhCR2) were stained
with B220 and b171 to establish the relative level of hCR2 expression on mature B
cells in these strains. The mean value of each group is shown next to each group
and illustrated by the horizontal bar. (c) BM cells were isolated from age and sex
matched hCR2high mice on the B6 and DBA background. Dot plots show B220-FITC+
c
1
ancubation with fix/perm (BD biosciences, Oxford, UK). Dot plots show B220-FITC+
ells expressed as hCR2-PE (Bly-4) versus anti-IgM-Cy5.5. Results shown are repre-
entative of 3 independent experiments involving 10 mice from each genotype in
otal.
ormed C3 fragments to CR2 in the C3 sufficient mice (data not
hown). When this analysis was subsequently carried out in the
3−/− background, we found that hCR2 expression levels on cells
hat expressed sIgM were not significantly different from those
efore sIgMwas expressed. Overall, these data suggest that the lev-
ls of hCR2 are tightly regulated on the mouse B cell at the point
f sIgM expression and that C3 and/or its break down components
lay an important part in this mechanism.
.4. Background strain influences the degree of B cell reduction in
CR2 tg mice
During our recent study using CIA, where the hCR2 tg was back-
rossed onto the DBA1/j background (Kulik et al., 2007), it quickly
ecame apparent that hCR2 expression levels on mature splenic B
ells isolated from both hCR2high and hCR2int mice were at low lev-
ls as determined by flow cytometry analysis. Considering the data
rom above, we studied hCR2 expression levels during B cell devel-
pment in the DBA.hCR2high mice in comparison to our standard
6 strain. We found that the expression level of hCR2 on the B220lo
cell population of the bone marrow in both hCR2high and hCR2int
ice was almost identical between the B6 and DBA strains of mice
Fig. 4a, R1). However, as the B cells matured (become B220high), B
ell surface expression of hCR2 was found to be significantly lower
n the DBA background than that seen in B6 background (Fig. 4a,
2). This was even more apparent in the mice expressing the inter-
ediate level of hCR2int, where the reduction in hCR2 expression
s minimal in the B6 strain but well defined in the DBA background.
hen this analysis was extended to include hCR2high mice on the
6lpr background, we found that there was no real change in hCR2
xpression levels on mature B cells between the B6 and B6lpr back-
rounds (Fig. 4b). As previously noted, these data are in contrast
o hCR2high mice devoid of C3 (B6.C3−/−) which have a marked
ncrease in hCR2 expression levels onmature B cells comparedwith
heirwild type B6 counterparts (Fig. 4b, Twohig et al., 2007). Analy-
is of surface IgM and hCR2 expression revealed that the reduction
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oells expressed as hCR2 (biotin 171+SA-PE) versus anti-IgM-Cy5.5 (extracellular).
0,000 B cellswere collected by FACS and results are representative of at least 5mice
nalysed for each strain.
n B cell expression of hCR2 in the DBA background appeared to
oincide with the expression of sIgM (Fig. 4c). This data demon-
trates that strain differences exist in respect to the extent towhich
CR2 is considered ‘excessive’ on the B cell surface during this stage
f B cell development. It also indicates that a commonmechanism is
I.Y. Pappworth et al. / Molecular Imm
Fig. 5. Peripheral B cell percentages aredependentonbackgroundstrain. Blood from
mice was collected into 20l of heparin and red cells lysed. B cells and T cells were
further identified by B220 and CD3, respectively. Fixed samples were then assessed
by flow cytometry. PBL were identified by their forward and side scatter profile and
the relative percentage of B220 positive cells falling in the lymphoid gate was cal-
culated for each strain of mouse as indicated. 15 C57Bl/6 (B6), 15 C57Bl/6.hCR2high
(B6hCR2), 6 C57Bl/6.C3−/− (C3−/−), 7 C57Bl/6.C3−/− .hCR2high (C3−/−hCR2), 15 C57Bl/6j-
Faslpr/Faslpr (B6lpr), 12 B6lpr.hCR2high (B6lpr hCR2), 8 DBA/1j (DBA) and 5 DBA/1j
.hCR2high (DBAhCR2) were analysed. Wild type mice (hCR2 negative) are represented
by the filled-in symbols for each strain and the open symbols represent mice that
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roup ofmice is illustrated by the horizontal line. The reduction in B cell percentages
from that normally seen in the hCR2 negative littermates) is shown directly above
he hCR2high expressing groups.
ikely to exist between these twostrainsofmice and that expression
f sIgM triggers cell death and the modulation of hCR2 expression
evels seen on mature B cells.
.5. DBA.hCR2high mice have significantly fewer B cells than B6lpr
r B6 backgrounds
Thefirst characteristic to bedescribed in the lambdahCR2 trans-
enic mice is the loss of mature B cells from blood. Analysis of PBL
ercentages suggested that up to 60% of normal B cells are deleted
n hCR2high compared with wild type B6 littermates (Marchbank
t al., 2002). Analysis of B cell percentages in B6, B6lpr and DBA
trains indicated that these mice display different intrinsic B cell
evels in the bloodwith B6 having the highest percentages followed
y B6lpr and DBA, respectively (Fig. 5). Despite our initial thoughts,
hat there may be a reduction in apoptosis on the B6lpr.hCR2high
ice, it was clear that peripheral B cell numbers were reduced in
similar manner in the B6lpr background as seen in the B6 back-
round (B6lpr.hCR2high 52% to hCR2high 53% of normal). However,
he expression of hCR2 on B cells in theDBA background results in a
urther significant reduction in peripheral B cells. In fact, B cells are
everely reduced in the DBA.hCR2high mice, with the percentage of
cells in the lymphoid gate dropping to less than 20% of normal (or
round 7% of total lymphocytes in the blood compared with nearly
0% in the hCR2 negative DBA littermates).
. Discussion
Most autoimmune disorders are characterized by the presence
f auto-antibodies and abnormalities of B-cell function (Browning,
006; Martin and Chan, 2006). However, the mechanism(s) that
eads to break down of tolerance in B cells remains elusive. There is
growing body of evidence that CR1/CR2 plays an important role in
aintaining and defining normal B cell function and thereby helps
D
t
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o prevent the onset of autoimmune disease (reviewed (Holers,
005)). Our own previous findings demonstrated that the hCR2high
icewerealmost completelyprotected fromorganspecificautoim-
une disease (using the CIA model) (Kulik et al., 2007) and raised
ur hopes that these mice were largely protected from all autoim-
une diseases.
These hopes were partially born out, in that B6lpr.hCR2high were
ound to produce significantly lower levels of ANA than B6lpr mice
hat did not express hCR2 (Fig. 1a). However, the levels of ANA
ere not reduced back to the levels found in the B6 strain (which
re largely refractory to spontaneous ANA generation (Izui et al.,
984; Theofilopoulos and Dixon, 1985; Theofilopoulos et al., 1985)
nd the data indicated that significant levels of auto-antibodies
till accumulate in the B6lpr.hCR2high mice. This was confirmed,
lbeit in a qualitative rather than a quantitative anti-ssDNA ELISA
Fig. 1b). Anti-dsDNA are generally accepted as one of the defin-
ng features of the MRLlpr model (Theofilopoulos and Dixon, 1985;
heofilopoulos et al., 1985), but this analysis demonstrated that
he number of animals with readily detectable anti-dsDNA reac-
ivity was not significantly different between the hCR2 expressing
ndnon-expressingB6lpr littermates. Thedifferencenotedbetween
sDNA and ANA results might be a result of the sensitivity of these
ifferent assays or may reflect a selective deletion of particular BCR
pecificities during B cell development in the presence of hCR2.
nalysis of deposited C3 and Ig in several randomly selected kid-
eys from B6lpr and B6lpr.hCR2high mice (data not shown) also
onfirmed that the protective effect of hCR2 expression was less
bvious than that seen in the CIA model (Kulik et al., 2007). Sig-
ificant increases in ANA and rheumatoid factor titres have been
ound in B6lpr and MRLlpr mice in the absence of CR2 but these
ave little negative effect with respect to renal function (Boackle
t al., 2004; Wu et al., 2002) and suggests that whilst CR2 is highly
mportant with respect to the type, level and specificity of auto-
ntibodies generated in the absence of Fas, it does not dramatically
lter the outcome of this autoimmune disease model. Due to a lim-
ted amount of sera remaining after the initial analysis, we were
nable to establish the effect of hCR2 on other auto-antibodies such
s rheumatoid factor but the data herein suggests that certain B
ell clones maybe lost in the B6lpr.hCR2high mice that are at least
artially beneficial with respect to development and accumulation
f ANA. However, as might be predicted from the CR2 knockout
tudies mentioned above (Boackle et al., 2004; Wu et al., 2002),
he presence of hCR2 is not sufficient to completely reverse the
utoimmune phenotype in this background.
Analysis of the percentage of B cells in the peripheral blood lym-
hocyte compartment suggest that there is a significantly higher
evel of B cell deletion in the DBA background (albeit in a smaller
xperimental group) than in the B6lpr background (Fig. 5). These
ata suggest that lack of available B cells in the DBA mice com-
ared to those available in the B6lpr mice could largely explain
he difference in hCR2s ability to protect against disease onset. A
ecent study by Yanaba et al. (2007), where B cells were depleted
sing anti-CD20 antibodies prior to running the CIA model, clearly
emonstrated the importance of B cells in driving disease in the
IA model. Interestingly, the level of B cell deletion (approximately
5%) and the initial outcomes of B cell deletion with anti-CD20 is
ighly similar to that noted in the DBA.hCR2high mice. These data
ontinue to support the idea that B cells play a significant role in the
athogenesis of CIA and consideringB cell numbers are not reduced
s significantly in the B6lpr.hCR2high background compared to the
BA.hCR2 background (Fig. 5), offer a very plausible explana-
ion for the difference in the level of protection noted in CIA on the
BA background versus the effects noted in B6lpr model.
The failure of “anergic-like” hCR2high B cells (Birrell et al., 2005)
o protect from onset of disease in the B6lpr model might fit with
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he fact that B cells contribute more than just auto-antibodies in
he autoimmune response in lupus-prone models, i.e. B cells have
n important APC role in these mice (Chan et al., 1997; Chan et
l., 1999). As T cell responses were found to be essentially normal
n the previous CIA experiment (on the DBA background) (Kulik et
l., 2007), it is probably fair to assume that the APC function of B
ells or DC remain intact in the B6lpr mice. Thus, in the B6lpr model
he ability of T cells to drive B cells to become autoreactive should
emain fully intact and suggests that the loss of B cell numbers and
he alterationof signallingpathways in the remainingB cell popula-
ion appears to be overcome in the B6lpr mice through autoreactive
cell help. Together, these data support the notion that the MRL
odel is primarily reliant on misdirected T cell function/tolerance
hilst the CIAmodel is primarily reliant onmisdirected B cell func-
ion/tolerance and thus effects from altering signal pathways via
CR and CR2 cross-linking are more likely to have a defined impact
n the CIA model.
We have previously postulated that expression of hCR2 in the
onemarrow influences the signal through thePre-BCR (Kulik et al.,
007), which is normally required to allow B cells to progress along
he B cell maturation pathway (Rolink and Melchers, 1996). Anal-
sis of apoptosis levels in the hCR2high mice established that they
ad an increased basal rate of apoptosis in both the bone marrow
nd spleen (Fig. 2). This data suggests that B cells in the hCR2high
ice are highly susceptible to apoptosis, particularly at the point
f surface IgM expression. The presence of C3 (Fig. 3) appears to
e linked directly to the reduction of CR2 expression level on the
cell surface (Fig. 4a) and suggests that hCR2, interacting with C3
nd the sIgM/BCR is interfering with the normal negative selection
rocess. This couldbe a result of hCR2modulating the level of signal
erceived from the sIgM. In order to investigate this assertion, we
re currently crossbreeding the hCR2high line with mice express-
ng only BCR with specificity for chicken lysozyme (HEL tg mice
Goodnow et al., 1988)).
The fact that genetic background and the selection of the naïve
cell repertoire have been linked to the susceptibility of mice to
utoimmune disease (Wang et al., 2003) supports the idea that
CR2 can amplify normal selective pressure in this model. Cer-
ainly B6 and the B6lpr strain have a marked decrease in B cells
ransiting the BM compared with hCR2 negative littermates but
urprisingly the DBA mice have the fewest surviving B cells in the
eriphery (Fig. 5) and suggests that they have a highly restricted
cell repertoire which is being further tightened in the presence
f hCR2. Direct analysis of B cell susceptibility to altered deletion
n B6lpr might be informative. However, it has already been estab-
ished that deletion of autoreactive B cells after BCR ligation occurs
nabated in the absence of Fas (Yoshida et al., 2000) and we found
hat the levels of B cells in the B6lpr.hCR2 mice were essentially
dentical to those seen in B6.hCR2 mice (Fig. 5). Thus, as the effects
f hCR2 expression appear to be exerted on the BCR signalling path-
ays it seems unlikely that significant differences would be seen
etween the hCR2high and B6lpr.hCR2high mice.
Corroborating evidence for enhanced BCR signalling being the
ikely mechanism behind the altered phenotype in the hCR2high
ice can be found in the altered patterns of tyrosine phosphory-
ated proteins in B cells from hCR2 tg mice before and after BCR
ross-linking (Kulik et al., 2007). Interestingly, mobilization of Ca2+
n immature B cells has been found to be much greater than that
een in mature B cells, presumably to amplify weak signals in the
M environment and delete autoreactive B cells from the reper-
oire (Benschop et al., 2001). It thus seems plausible that additional
ignal amplification via hCR2 in the BM is likely to disrupt these
ighly sensitive signalling networks resulting in the higher levels
f apoptosis found and the increase in anergy in the remaining B
ells.
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The data presented here continues to suggest that CR2 expres-
ion levels are a critical factor in determining B cell function. The
ignal generated through hCR2 is apparently a modifier of the BCR
ignal since numbers of pro-B cells and hCR2 expression levels are
normal’ until surface BCR is expressed in the BM. It is possible
hat additional signalling molecules expressed at the same point
s sIgM may interact with hCR2 and thus sIgM might only be a
arker of the time when such changes take place. Nevertheless, it
s clear that examination of the proteins and signalling molecules
eing altered in the hCR2high mice at the point that of BCR, hCR2
nd (self) antigen contact will provide a fuller understanding of
he molecules involved in B cell survival and selection of the BCR
epertoire. This should also provide a greater understanding of the
echanisms that predispose B cells to break tolerance in certain
enetic backgrounds.
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